Literature DB >> 26825606

Hepatocyte nuclear factor 6 inhibits the growth and metastasis of cholangiocarcinoma cells by regulating miR-122.

Huaqiang Zhu1, Yuetang Mi2, Xian Jiang3, Xu Zhou1, Rui Li2, Zheng Wei3, Hongchi Jiang3, Jun Lu1, Xueying Sun4,5.   

Abstract

PURPOSE: Hepatocyte nuclear factor 6 (HNF6) is a liver-enriched transcription factor and highly expressed in mature bile duct epithelial cells. This study sought to investigate the role of HNF6, particularly the molecular mechanisms for how HNF6 is involved in the growth and metastasis of cholangiocarcinoma (CCA) cells.
METHODS: The expression of HNF6, miR-122 and key molecules was examined by Western blot analysis and real-time RT-PCR. Stable transfectants, HCCC-HNF(low) and RBE-HNF(high), were generated from human CCA HCCC-9810 and RBE cells, respectively. The regulatory effect of HNF6 on miR-122 was evaluated by luciferase reporter assay. Cell proliferation, cycle distribution, migration and invasion were analyzed. The xenograft model was used to assess the effects of HNF6 overexpression on tumorigenesis, growth, metastasis and therapeutic potentials.
RESULTS: Human CCA tissues and cells expressed lower levels of HNF6, which positively correlated with miR-122. HNF6 regulated the expression of miR-122 by stimulating its promoter. HNF6 overexpression inhibited cell proliferation by inducing cell cycle arrest at G1 phase through regulating miR-122, cyclin G1 and insulin-like growth factor-1 receptor. HNF6 inhibited the migration and invasion of CCA cells by regulating matrix metalloproteinase-2 and metalloproteinase-9, reversion-inducing-cysteine-rich protein with kazal motifs, E-cadherin and N-cadherin. Co-transfection of anti-miR-122 abrogated the effects of HNF6. HNF6 overexpression inhibited the ability of cells to form tumors and to metastasize to the lungs of mice, and the growth of established tumors.
CONCLUSIONS: The results indicate that HNF6 may serve as a tumor suppressor by regulating miR-122, and its overexpression may represent a mechanism-based therapy for CCA.

Entities:  

Keywords:  Cholangiocarcinoma; Hepatocyte nuclear factor 6; Metastasis; MicroRNA-122; Proliferation

Mesh:

Substances:

Year:  2016        PMID: 26825606     DOI: 10.1007/s00432-016-2121-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  35 in total

1.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

2.  Overexpression of miR-122 promotes the hepatic differentiation and maturation of mouse ESCs through a miR-122/FoxA1/HNF4a-positive feedback loop.

Authors:  Xiao-Geng Deng; Rong-Lin Qiu; Yao-Hao Wu; Zhi-Xi Li; Ping Xie; Jie Zhang; Jia-Jia Zhou; Le-Xiang Zeng; Jing Tang; Anu Maharjan; Jie-Min Deng
Journal:  Liver Int       Date:  2013-07-09       Impact factor: 5.828

3.  Hepatocyte nuclear factor 6 activates the transcription of CYP3A4 in hepatocyte-like cells differentiated from human induced pluripotent stem cells.

Authors:  Takamitsu Sasaki; Shogo Takahashi; Yoshihiro Numata; Masayo Narita; Yutaka Tanaka; Takeshi Kumagai; Yuki Kondo; Tamihide Matsunaga; Shigeru Ohmori; Kiyoshi Nagata
Journal:  Drug Metab Pharmacokinet       Date:  2013-01-01       Impact factor: 3.614

4.  Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells.

Authors:  Leina Ma; Jia Liu; Junjie Shen; Li Liu; Jia Wu; Wei Li; Jingjing Luo; Qing Chen; Cheng Qian
Journal:  Cancer Biol Ther       Date:  2010-04-01       Impact factor: 4.742

Review 5.  Pathophysiologic role of hepatocyte nuclear factor 6.

Authors:  Kewei Wang; Ai-Xuan Holterman
Journal:  Cell Signal       Date:  2011-08-27       Impact factor: 4.315

6.  The hepatocyte nuclear factor 6 (HNF6) and FOXA2 are key regulators in colorectal liver metastases.

Authors:  F Lehner; U Kulik; J Klempnauer; J Borlak
Journal:  FASEB J       Date:  2007-02-05       Impact factor: 5.191

7.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Authors:  Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

8.  A mammalian microRNA expression atlas based on small RNA library sequencing.

Authors:  Pablo Landgraf; Mirabela Rusu; Robert Sheridan; Alain Sewer; Nicola Iovino; Alexei Aravin; Sébastien Pfeffer; Amanda Rice; Alice O Kamphorst; Markus Landthaler; Carolina Lin; Nicholas D Socci; Leandro Hermida; Valerio Fulci; Sabina Chiaretti; Robin Foà; Julia Schliwka; Uta Fuchs; Astrid Novosel; Roman-Ulrich Müller; Bernhard Schermer; Ute Bissels; Jason Inman; Quang Phan; Minchen Chien; David B Weir; Ruchi Choksi; Gabriella De Vita; Daniela Frezzetti; Hans-Ingo Trompeter; Veit Hornung; Grace Teng; Gunther Hartmann; Miklos Palkovits; Roberto Di Lauro; Peter Wernet; Giuseppe Macino; Charles E Rogler; James W Nagle; Jingyue Ju; F Nina Papavasiliou; Thomas Benzing; Peter Lichter; Wayne Tam; Michael J Brownstein; Andreas Bosio; Arndt Borkhardt; James J Russo; Chris Sander; Mihaela Zavolan; Thomas Tuschl
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

9.  Loss of HNF6 expression correlates with human pancreatic cancer progression.

Authors:  Kelly R Pekala; Xidi Ma; Peter A Kropp; Christine P Petersen; Courtney W Hudgens; Christine H Chung; Chanjuan Shi; Nipun B Merchant; Anirban Maitra; Anna L Means; Maureen A Gannon
Journal:  Lab Invest       Date:  2014-03-17       Impact factor: 5.662

10.  Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells.

Authors:  Jialin He; Kai Zhao; Lu Zheng; Zhizhen Xu; Wei Gong; Shan Chen; Xiaodong Shen; Gang Huang; Min Gao; Yijun Zeng; Yan Zhang; Fengtian He
Journal:  Mol Cancer       Date:  2015-08-25       Impact factor: 27.401

View more
  3 in total

1.  Diagnostic and therapeutic potentials of microRNAs in cholangiopathies.

Authors:  Indsey Kennedy; Heather Francis; Fanyin Meng; Shannon Glaser; Gianfranco Alpini
Journal:  Liver Res       Date:  2017-04-26

Review 2.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

3.  LncRNA TTN-AS1 promotes the progression of cholangiocarcinoma via the miR-320a/neuropilin-1 axis.

Authors:  Huaqiang Zhu; Bo Zhai; Changjun He; Ziyi Li; Hengjun Gao; Zheyu Niu; Xian Jiang; Jun Lu; Xueying Sun
Journal:  Cell Death Dis       Date:  2020-08-15       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.